Current Prophylaxis and Treatment Approaches for Acute Graft-Versus-Host Disease in Haematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukaemia

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2022 Jan 24

PMID 35071133

Authors

Matthias Wolfl

Muna Qayed

Maria Isabel Benitez Carabante

Tomas Sykora

Halvard Bonig

Anita Lawitschka

Cristina Diaz-de-Heredia

Affiliations

Soon will be listed here.

Abstract

Acute graft-versus-host disease (aGvHD) continues to be a leading cause of morbidity and mortality following allogeneic haematopoietic stem cell transplantation (HSCT). However, higher event-free survival (EFS) was observed in patients with acute lymphoblastic leukaemia (ALL) and grade II aGvHD vs. patients with no or grade I GvHD in the randomised, controlled, open-label, international, multicentre Phase III For Omitting Radiation Under Majority age (FORUM) trial. This finding suggests that moderate-severity aGvHD is associated with a graft-versus-leukaemia effect which protects against leukaemia recurrence. In order to optimise the benefits of HSCT for leukaemia patients, reduction of non-relapse mortality-which is predominantly caused by severe GvHD-is of utmost importance. Herein, we review contemporary prophylaxis and treatment options for aGvHD in children with ALL and the key challenges of aGvHD management, focusing on maintaining the graft-versus-leukaemia effect without increasing the severity of GvHD.

Citing Articles

Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.

Baccelli F, Gottardi F, Muratore E, Leardini D, Grasso A, Gori D Bone Marrow Transplant. 2024; 59(6):765-776.

PMID: 38402346 PMC: 11161405. DOI: 10.1038/s41409-024-02252-z.

Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study.

Seftel M, Pasic I, Parmar G, Bucher O, Allan D, Bhella S Curr Oncol. 2023; 30(11):9953-9967.

PMID: 37999143 PMC: 10669983. DOI: 10.3390/curroncol30110723.

References

Pulsipher M, Langholz B, Wall D, Schultz K, Bunin N, Carroll W . Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?. Bone Marrow Transplant. 2015; 50(9):1173-9. PMC: 4573663. DOI: 10.1038/bmt.2015.103. View

Bonig H, Kuci Z, Kuci S, Bakhtiar S, Basu O, Bug G . Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients. Cells. 2019; 8(12). PMC: 6952775. DOI: 10.3390/cells8121577. View

Parfitt J, Jayakumar S, Driman D . Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol. 2008; 32(9):1367-72. DOI: 10.1097/pas.0b013e31816bf3fe. View

Cuvelier G, Nemecek E, Wahlstrom J, Kitko C, Lewis V, Schechter T . Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019; 134(3):304-316. PMC: 6911839. DOI: 10.1182/blood.2019000216. View

Hockenbery D, Cruickshank S, Rodell T, Gooley T, Schuening F, Rowley S . A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007; 109(10):4557-63. DOI: 10.1182/blood-2006-05-021139. View

Rocha V, Cornish J, Sievers E, Filipovich A, Locatelli F, Peters C . Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001; 97(10):2962-71. DOI: 10.1182/blood.v97.10.2962. View

Chaudhry M, Velardi E, Malard F, van den Brink M . Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. J Immunol. 2016; 198(1):40-46. DOI: 10.4049/jimmunol.1601100. View

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

Dini G, Zecca M, Balduzzi A, Messina C, Masetti R, Fagioli F . No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood. 2011; 118(25):6683-90. DOI: 10.1182/blood-2011-05-354233. View

10.

Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X . Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study. Front Immunol. 2018; 9:2195. PMC: 6167440. DOI: 10.3389/fimmu.2018.02195. View

11.

Jagasia M, Arora M, Flowers M, Chao N, McCarthy P, Cutler C . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2011; 119(1):296-307. PMC: 3251233. DOI: 10.1182/blood-2011-06-364265. View

12.

Wang Y, Wu D, Liu Q, Xu L, Liu K, Zhang X . Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019; 12(1):88. PMC: 6724335. DOI: 10.1186/s13045-019-0781-y. View

13.

Zeiser R, Blazar B . Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179. PMC: 6034180. DOI: 10.1056/NEJMra1609337. View

14.

Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A . Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2013; 49(2):168-73. DOI: 10.1038/bmt.2013.107. View

15.

Carpenter P, MacMillan M . Management of acute graft-versus-host disease in children. Pediatr Clin North Am. 2010; 57(1):273-95. PMC: 3227683. DOI: 10.1016/j.pcl.2009.11.007. View

16.

Mulrooney D, Hyun G, Ness K, Bhakta N, Pui C, Ehrhardt M . The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019; 6(6):e306-e316. PMC: 6756152. DOI: 10.1016/S2352-3026(19)30050-X. View

17.

Balduzzi A, Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A . Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?. Br J Haematol. 2014; 164(3):396-408. DOI: 10.1111/bjh.12639. View

18.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10):2062-8. PMC: 4854652. DOI: 10.1038/leu.2015.212. View

19.

Paviglianiti A, Dalle J, Ayas M, Boelens J, Volt F, Iori A . Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biol Blood Marrow Transplant. 2017; 24(4):799-805. DOI: 10.1016/j.bbmt.2017.12.790. View

20.

Cornelissen J, Carston M, Kollman C, KING R, Dekker A, Lowenberg B . Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001; 97(6):1572-7. DOI: 10.1182/blood.v97.6.1572. View